Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.

@article{PedralSampaio2004EfficacyAS,
  title={Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.},
  author={Diana Brasil Pedral-Sampaio and Carmosina R Alves and Eduardo M Netto and Carlos R Brites and Adriano Silva Oliveira and Roberto Badar{\'o}},
  journal={The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases},
  year={2004},
  volume={8 3},
  pages={211-6}
}
Forty-nine AIDS patients, most of who were antiretroviral therapy (ARV) naive, with active tuberculosis, were treated with Rifampin 600 mg, Isoniazid 400 mg and Pirazinamide 2 g daily. They also received ARV, consisting of Efavirenz (600 mg/day) plus 2 NRTIs. All patients were prospectively followed for at least 24 months. Baselines were: male/female ratio 2:1, mean age 34.7 +/- 9.4 yrs; weight 51 +/- 9.0 kg, viral load 5.6 +/- 0.6 logs, CD4 cell count 101 +/- 128 cells/ mm3. Follow up mean… CONTINUE READING